Aurobindo Pharma Ltd
NSE:AUROPHARMA
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Price:
1 350.6
INR
0.09%
Market Closed
Market Cap:
₹784.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Aurobindo Pharma Ltd
NSE:AUROPHARMA
|
IN |
Multiples-Based Value
The Multiples-Based Value of one
AUROPHARMA
stock under the Base Case scenario is
1 417.96
INR.
Compared to the current market price of 1 350.6 INR,
Aurobindo Pharma Ltd
is
Undervalued by 5%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AUROPHARMA
Multiples-Based Value
1 417.96
INR
Undervaluation 5%
Multiples Across Competitors
AUROPHARMA Competitors Multiples
Aurobindo Pharma Ltd Competitors
Aurobindo Pharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Aurobindo Pharma Ltd
NSE:AUROPHARMA
|
783.7B INR | 2.3 | 22.3 | 10.4 | 13.9 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.5 | 42.6 | 28.7 | 30.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6 | 21.2 | 14.7 | 18.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.2 | 30.1 | 16.6 | 23.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.5 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.5 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.6B CHF | 5.2 | 20.8 | 12.9 | 16.5 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.4 | 7.7 | 9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
88.7B GBP | 2.7 | 15.5 | 8.4 | 10.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
